ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1, 2017 at 4:30 p.m. ET
BOSTON, April 24, 2017-- ZIOPHARM Oncology, Inc., a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday, ...
- GlobeNewswire•5 days ago
ZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting
BOSTON, April 20, 2017-- ZIOPHARM Oncology, Inc., a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter, dose-escalation ...
- Motley Fool•7 days ago
The billionaire-led company's growth strategy promises that the stock's best days are ahead.
XON : Summary for Intrexon Corporation Common Sto - Yahoo Finance
Intrexon Corporation (XON)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||20.26 - 21.25|
|52 Week Range||18.41 - 32.90|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-13.36|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|